Evidence map›Paper›PMID 23341662›Full record

ArticleCanadian family physician Medecin de famille canadien2013

Family practice patients' use of acetylsalicylic acid for cardiovascular disease prevention.

Michael Kolber, Nadder Sharif, Raelene Marceau, Olga Szafran

Abstract readMulticenter Study
PubMed Full text at PMC
In one paragraph

Article in Canadian family physician Medecin de famille canadien, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Should aspirin be used for the primary prevention of cardiovascular disease in the general population?Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2015
    Article
  3. Article
  4. Article
  5. Could Low Doses Acetylsalicylic Acid Prevent Thrombotic Complications in COVID-19 Patients?Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Michael KolberDepartment of Family Medicine, 1706 College Plaza, University of Alberta, Edmonton, AB T6G 2C8. mkolber@ualberta.ca
Nadder Sharif
Raelene Marceau
Olga Szafran
University of Alberta · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo determine the prevalence of acetylsalicylic acid (ASA) use among family practice patients and the proportions of patients using ASA for primary and secondary cardiovascular prevention.

designCross-sectional, self-reported, waiting room questionnaire.

settingTwo family medicine clinics in Alberta.

participantsPatients 50 years of age and older.

main outcome measuresOverall prevalence of ASA use, proportion of ASA use for primary or secondary cardiovascular prevention, ASA use by patient age and sex, the proportion of patients who initiated ASA therapy on the advice of a physician, adverse events, and patient beliefs about ASA therapy.

resultsA total of 807 patients completed the questionnaire; the response rate was 89.1%. Overall, 39.8% of patients reported taking ASA regularly. Of those who took ASA, 87.0% did so for cardiovascular prevention (53.1% for primary prevention and 46.9% for secondary prevention). Of patients taking ASA for primary prevention, 62.8% did so upon the advice of their family physicians. Patients who took ASA believed that the benefits of taking ASA outweighed the risks; those who did not take ASA were unsure of the benefit-to-risk profile.

conclusionMany family practice patients take ASA, and more than half of those taking ASA take it for primary cardiovascular prevention. Family physicians appear to have an influence on patients' decisions to take ASA. Educating family physicians and patients about the potential benefits and risks of ASA therapy would help promote the use of ASA in those who might receive the greatest overall benefit.

Indexed as

AgedAged, 80 and overAlbertaAmbulatory Care FacilitiesAspirinCardiovascular DiseasesCross-Sectional StudiesFamily PracticeFemaleHumansMaleMiddle AgedPlatelet Aggregation InhibitorsPrimary PreventionRural PopulationSecondary PreventionAspirinPlatelet Aggregation Inhibitors

Identifiers

PMID23341662
PMCPMC3555659
OpenAlexW2157424947

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.